 Elaine Lam
Concepts (314)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 37 | 2026 | 234 | 7.030 |
Why?
| | Kidney Neoplasms | 40 | 2026 | 412 | 6.590 |
Why?
| | Prostatic Neoplasms | 13 | 2023 | 978 | 2.830 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 75 | 1.440 |
Why?
| | Antineoplastic Agents | 15 | 2024 | 2197 | 1.290 |
Why?
| | Prostate-Specific Antigen | 4 | 2023 | 162 | 1.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 12 | 2025 | 988 | 1.110 |
Why?
| | Protein Kinase Inhibitors | 12 | 2026 | 970 | 1.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 15 | 2025 | 1958 | 1.000 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 113 | 0.900 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2025 | 20 | 0.900 |
Why?
| | Neoplasms | 10 | 2023 | 2884 | 0.900 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2025 | 199 | 0.840 |
Why?
| | Carcinoma, Transitional Cell | 4 | 2025 | 68 | 0.800 |
Why?
| | Seminoma | 2 | 2021 | 20 | 0.780 |
Why?
| | Carcinoma, Medullary | 2 | 2013 | 16 | 0.710 |
Why?
| | Aged | 37 | 2026 | 25947 | 0.690 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 28 | 0.670 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2025 | 259 | 0.660 |
Why?
| | Male | 60 | 2026 | 72406 | 0.650 |
Why?
| | Pyridines | 6 | 2026 | 605 | 0.640 |
Why?
| | Teratoma | 1 | 2021 | 120 | 0.630 |
Why?
| | Pneumocystis carinii | 1 | 2020 | 12 | 0.630 |
Why?
| | Spinal Cord Compression | 1 | 2020 | 22 | 0.630 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2025 | 642 | 0.620 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 42 | 0.620 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2020 | 34 | 0.620 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.570 |
Why?
| | Humans | 87 | 2026 | 144957 | 0.570 |
Why?
| | Middle Aged | 39 | 2026 | 35928 | 0.540 |
Why?
| | TWEAK Receptor | 1 | 2017 | 6 | 0.540 |
Why?
| | Prednisone | 3 | 2020 | 221 | 0.540 |
Why?
| | Pyrazoles | 3 | 2022 | 510 | 0.520 |
Why?
| | Anilides | 5 | 2023 | 84 | 0.520 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 15 | 0.510 |
Why?
| | Sulfonamides | 3 | 2015 | 581 | 0.510 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1322 | 0.500 |
Why?
| | Plant Extracts | 1 | 2018 | 187 | 0.500 |
Why?
| | Adrenal Cortex Hormones | 1 | 2020 | 479 | 0.500 |
Why?
| | Aged, 80 and over | 17 | 2025 | 8279 | 0.480 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2015 | 194 | 0.460 |
Why?
| | Neoplasm Metastasis | 9 | 2020 | 695 | 0.460 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 1141 | 0.450 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 79 | 0.440 |
Why?
| | Brain Neoplasms | 2 | 2021 | 1322 | 0.430 |
Why?
| | Paclitaxel | 3 | 2022 | 256 | 0.420 |
Why?
| | Everolimus | 2 | 2025 | 111 | 0.420 |
Why?
| | Patient Reported Outcome Measures | 4 | 2025 | 489 | 0.410 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 3 | 2022 | 53 | 0.410 |
Why?
| | Interleukin-2 | 2 | 2014 | 437 | 0.410 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.400 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1524 | 0.380 |
Why?
| | Urologic Neoplasms | 2 | 2025 | 31 | 0.370 |
Why?
| | Nephrectomy | 4 | 2024 | 158 | 0.360 |
Why?
| | Treatment Outcome | 17 | 2025 | 11695 | 0.360 |
Why?
| | Retrospective Studies | 18 | 2024 | 17101 | 0.360 |
Why?
| | Epothilones | 1 | 2011 | 2 | 0.350 |
Why?
| | Angiomyolipoma | 1 | 2011 | 21 | 0.350 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2025 | 1182 | 0.340 |
Why?
| | Androgen Antagonists | 3 | 2020 | 92 | 0.340 |
Why?
| | Deoxycytidine | 2 | 2010 | 221 | 0.330 |
Why?
| | Multicenter Studies as Topic | 1 | 2012 | 405 | 0.320 |
Why?
| | Benzenesulfonates | 1 | 2010 | 21 | 0.320 |
Why?
| | Suramin | 1 | 2010 | 7 | 0.320 |
Why?
| | Adult | 27 | 2025 | 40506 | 0.320 |
Why?
| | Lung Neoplasms | 4 | 2025 | 2642 | 0.320 |
Why?
| | Maximum Tolerated Dose | 6 | 2022 | 212 | 0.290 |
Why?
| | Radiosurgery | 3 | 2019 | 401 | 0.280 |
Why?
| | Female | 35 | 2026 | 78376 | 0.280 |
Why?
| | Immunotherapy | 5 | 2024 | 657 | 0.280 |
Why?
| | Indenes | 2 | 2025 | 6 | 0.270 |
Why?
| | Fluorouracil | 1 | 2008 | 235 | 0.270 |
Why?
| | Disease Progression | 3 | 2021 | 2852 | 0.260 |
Why?
| | Bone Neoplasms | 2 | 2023 | 256 | 0.260 |
Why?
| | Quinazolines | 1 | 2008 | 266 | 0.250 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2013 | 421 | 0.250 |
Why?
| | Neoplasm Staging | 7 | 2017 | 1465 | 0.250 |
Why?
| | Practice Guidelines as Topic | 4 | 2024 | 1563 | 0.240 |
Why?
| | Platinum | 2 | 2024 | 50 | 0.240 |
Why?
| | Drug Administration Schedule | 3 | 2021 | 783 | 0.240 |
Why?
| | Thyroid Neoplasms | 1 | 2010 | 346 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2026 | 72 | 0.230 |
Why?
| | Sulfones | 2 | 2017 | 127 | 0.220 |
Why?
| | B7-H1 Antigen | 2 | 2025 | 241 | 0.220 |
Why?
| | Microsatellite Instability | 1 | 2025 | 54 | 0.220 |
Why?
| | Prognosis | 5 | 2023 | 4293 | 0.220 |
Why?
| | Phenylurea Compounds | 4 | 2016 | 112 | 0.220 |
Why?
| | Benzoxazoles | 2 | 2022 | 20 | 0.200 |
Why?
| | Melanoma | 2 | 2025 | 761 | 0.200 |
Why?
| | Ipilimumab | 2 | 2021 | 40 | 0.200 |
Why?
| | Taste | 1 | 2026 | 240 | 0.200 |
Why?
| | Taxoids | 2 | 2017 | 116 | 0.200 |
Why?
| | Taste Buds | 1 | 2026 | 212 | 0.200 |
Why?
| | Multiple Sclerosis | 2 | 2019 | 484 | 0.190 |
Why?
| | Bevacizumab | 2 | 2020 | 167 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 5 | 2024 | 966 | 0.180 |
Why?
| | Mastectomy | 1 | 2023 | 162 | 0.180 |
Why?
| | Quantitative Trait Loci | 1 | 2024 | 374 | 0.180 |
Why?
| | Pyrimidines | 3 | 2022 | 533 | 0.180 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 40 | 0.170 |
Why?
| | Administration, Oral | 4 | 2024 | 848 | 0.170 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 31 | 0.160 |
Why?
| | Celecoxib | 2 | 2012 | 41 | 0.160 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 139 | 0.160 |
Why?
| | Carboplatin | 1 | 2021 | 160 | 0.160 |
Why?
| | Bariatric Surgery | 1 | 2024 | 242 | 0.160 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 381 | 0.160 |
Why?
| | Syndrome | 1 | 2021 | 380 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 437 | 0.160 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1268 | 0.160 |
Why?
| | Quality of Life | 2 | 2025 | 3192 | 0.160 |
Why?
| | Genomics | 1 | 2025 | 836 | 0.150 |
Why?
| | Azepines | 1 | 2020 | 107 | 0.150 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 48 | 0.150 |
Why?
| | Antiemetics | 1 | 2020 | 49 | 0.150 |
Why?
| | Thrombosis | 1 | 2023 | 393 | 0.150 |
Why?
| | Homologous Recombination | 1 | 2019 | 36 | 0.150 |
Why?
| | Fatal Outcome | 1 | 2020 | 307 | 0.150 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 451 | 0.150 |
Why?
| | Morpholines | 1 | 2020 | 129 | 0.150 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2019 | 70 | 0.150 |
Why?
| | Pharyngitis | 1 | 2019 | 25 | 0.140 |
Why?
| | Streptococcus | 1 | 2019 | 29 | 0.140 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1915 | 0.140 |
Why?
| | Disease-Free Survival | 4 | 2016 | 769 | 0.140 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 21 | 0.140 |
Why?
| | Drug Hypersensitivity | 1 | 2020 | 90 | 0.140 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2019 | 91 | 0.140 |
Why?
| | Feedback | 1 | 2019 | 181 | 0.140 |
Why?
| | Mutation | 2 | 2025 | 4099 | 0.140 |
Why?
| | Indans | 1 | 2017 | 13 | 0.130 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2016 | 82 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 636 | 0.130 |
Why?
| | Interferon beta-1b | 1 | 2017 | 2 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2026 | 927 | 0.130 |
Why?
| | Niacinamide | 3 | 2016 | 86 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1407 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 15 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2023 | 783 | 0.130 |
Why?
| | Erythrocytes, Abnormal | 1 | 2016 | 14 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2147 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2022 | 2032 | 0.120 |
Why?
| | Hematologic Diseases | 1 | 2016 | 66 | 0.120 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 82 | 0.120 |
Why?
| | DNA Damage | 1 | 2019 | 430 | 0.120 |
Why?
| | Streptococcal Infections | 1 | 2019 | 169 | 0.120 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 3550 | 0.120 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 463 | 0.120 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 13 | 0.120 |
Why?
| | Indazoles | 2 | 2015 | 80 | 0.120 |
Why?
| | Problem Solving | 1 | 2017 | 156 | 0.120 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 2015 | 38 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 463 | 0.120 |
Why?
| | Angiopoietin-1 | 1 | 2015 | 12 | 0.110 |
Why?
| | Angiopoietin-2 | 1 | 2015 | 15 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2365 | 0.110 |
Why?
| | Pyrroles | 1 | 2016 | 218 | 0.110 |
Why?
| | Fatigue | 2 | 2022 | 366 | 0.110 |
Why?
| | Receptor, IGF Type 1 | 1 | 2015 | 64 | 0.110 |
Why?
| | Kidney Glomerulus | 1 | 2015 | 128 | 0.110 |
Why?
| | Imidazoles | 2 | 2015 | 254 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2015 | 103 | 0.110 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 253 | 0.110 |
Why?
| | Nanoparticles | 1 | 2021 | 520 | 0.110 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 127 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2925 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3869 | 0.100 |
Why?
| | Prefrontal Cortex | 1 | 2017 | 328 | 0.100 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 109 | 0.100 |
Why?
| | Prostatectomy | 1 | 2013 | 93 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2017 | 705 | 0.100 |
Why?
| | Glycine | 1 | 2014 | 187 | 0.090 |
Why?
| | Indoles | 1 | 2016 | 501 | 0.090 |
Why?
| | Cohort Studies | 5 | 2021 | 5965 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 675 | 0.090 |
Why?
| | Glomerular Filtration Rate | 1 | 2015 | 760 | 0.090 |
Why?
| | Tubulin Modulators | 1 | 2011 | 11 | 0.090 |
Why?
| | Quinolines | 1 | 2013 | 193 | 0.090 |
Why?
| | Metabolic Clearance Rate | 1 | 2011 | 115 | 0.090 |
Why?
| | Emotions | 1 | 2017 | 578 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1839 | 0.080 |
Why?
| | Arthralgia | 1 | 2011 | 61 | 0.080 |
Why?
| | Area Under Curve | 1 | 2011 | 331 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1054 | 0.080 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2011 | 133 | 0.080 |
Why?
| | Diarrhea | 1 | 2011 | 192 | 0.080 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 2 | 2022 | 139 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2456 | 0.080 |
Why?
| | Molecular Structure | 1 | 2011 | 501 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2010 | 41 | 0.080 |
Why?
| | Biopsy | 1 | 2013 | 1077 | 0.080 |
Why?
| | Survival Rate | 3 | 2020 | 2092 | 0.080 |
Why?
| | Nomograms | 1 | 2010 | 59 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2022 | 2738 | 0.070 |
Why?
| | Decision Making | 1 | 2017 | 980 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1718 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2010 | 222 | 0.070 |
Why?
| | Drug Synergism | 1 | 2010 | 357 | 0.070 |
Why?
| | Capecitabine | 1 | 2008 | 57 | 0.070 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 423 | 0.070 |
Why?
| | Adenine | 2 | 2022 | 339 | 0.070 |
Why?
| | Positron-Emission Tomography | 1 | 2010 | 343 | 0.070 |
Why?
| | Proteinuria | 1 | 2008 | 102 | 0.070 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2008 | 68 | 0.060 |
Why?
| | Dysgeusia | 1 | 2026 | 5 | 0.060 |
Why?
| | Young Adult | 4 | 2024 | 14126 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5417 | 0.060 |
Why?
| | Creatinine | 1 | 2008 | 506 | 0.060 |
Why?
| | Risk | 1 | 2008 | 911 | 0.060 |
Why?
| | Optical Illusions | 1 | 2005 | 2 | 0.060 |
Why?
| | Urothelium | 1 | 2025 | 33 | 0.060 |
Why?
| | Risk Factors | 2 | 2020 | 10792 | 0.050 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2024 | 18 | 0.050 |
Why?
| | Cell Lineage | 1 | 2026 | 376 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2024 | 67 | 0.050 |
Why?
| | Prospective Studies | 3 | 2021 | 7997 | 0.050 |
Why?
| | Mastectomy, Segmental | 1 | 2023 | 108 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2024 | 245 | 0.050 |
Why?
| | RNA Interference | 1 | 2024 | 476 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 2171 | 0.040 |
Why?
| | Disease Management | 2 | 2017 | 647 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2024 | 635 | 0.040 |
Why?
| | Cisplatin | 1 | 2023 | 334 | 0.040 |
Why?
| | Nephritis, Interstitial | 1 | 2020 | 11 | 0.040 |
Why?
| | International Agencies | 1 | 2020 | 30 | 0.040 |
Why?
| | Drug Evaluation | 1 | 2020 | 79 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 62 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 63 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 382 | 0.040 |
Why?
| | Nausea | 1 | 2020 | 111 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2017 | 1311 | 0.040 |
Why?
| | Hong Kong | 1 | 2019 | 8 | 0.040 |
Why?
| | Vomiting | 1 | 2020 | 130 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 334 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 7183 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2114 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2026 | 3125 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 732 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 332 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2026 | 1500 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2026 | 2050 | 0.030 |
Why?
| | Central Nervous System | 1 | 2020 | 281 | 0.030 |
Why?
| | Transcription Factors | 1 | 2026 | 1742 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 482 | 0.030 |
Why?
| | Retreatment | 1 | 2017 | 77 | 0.030 |
Why?
| | Databases, Factual | 1 | 2023 | 1486 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1048 | 0.030 |
Why?
| | United States | 2 | 2017 | 15988 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 52 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2019 | 230 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 930 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 33 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2020 | 548 | 0.030 |
Why?
| | Antimicrobial Stewardship | 1 | 2019 | 130 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 475 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 257 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3608 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 359 | 0.030 |
Why?
| | Neutrophils | 1 | 2022 | 1134 | 0.030 |
Why?
| | Mice | 2 | 2026 | 18365 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 1031 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 39 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 47 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2015 | 16 | 0.030 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 35 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 157 | 0.030 |
Why?
| | Reaction Time | 1 | 2017 | 438 | 0.030 |
Why?
| | Craniocerebral Trauma | 1 | 2017 | 176 | 0.030 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 237 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 309 | 0.030 |
Why?
| | Radiotherapy | 1 | 2015 | 206 | 0.030 |
Why?
| | Organ Size | 1 | 2015 | 463 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 149 | 0.030 |
Why?
| | Postoperative Period | 1 | 2015 | 354 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 883 | 0.030 |
Why?
| | Demography | 1 | 2015 | 288 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 142 | 0.030 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 52 | 0.030 |
Why?
| | Animals | 3 | 2026 | 38109 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 205 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1135 | 0.030 |
Why?
| | Drug Interactions | 1 | 2015 | 401 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2015 | 212 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 539 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2015 | 629 | 0.020 |
Why?
| | Cell Survival | 1 | 2015 | 1098 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2947 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1325 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1137 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2029 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2014 | 389 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 434 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 623 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4275 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 826 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 629 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2119 | 0.020 |
Why?
| | Reagent Strips | 1 | 2008 | 8 | 0.020 |
Why?
| | Primary Health Care | 1 | 2019 | 1734 | 0.020 |
Why?
| | Urinalysis | 1 | 2008 | 80 | 0.020 |
Why?
| | Albuminuria | 1 | 2008 | 190 | 0.020 |
Why?
| | Diagnostic Tests, Routine | 1 | 2008 | 108 | 0.020 |
Why?
| | Vision, Monocular | 1 | 2005 | 4 | 0.010 |
Why?
| | Psychophysics | 1 | 2005 | 15 | 0.010 |
Why?
| | Eye Enucleation | 1 | 2005 | 14 | 0.010 |
Why?
| | Vision, Binocular | 1 | 2005 | 47 | 0.010 |
Why?
| | Orientation | 1 | 2005 | 50 | 0.010 |
Why?
| | Adolescent | 2 | 2020 | 22453 | 0.010 |
Why?
| | Pattern Recognition, Visual | 1 | 2005 | 105 | 0.010 |
Why?
| | Photic Stimulation | 1 | 2005 | 264 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1990 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 5233 | 0.010 |
Why?
| | Pregnancy | 1 | 2008 | 7191 | 0.010 |
Why?
| | Child | 1 | 2005 | 22657 | 0.000 |
Why?
|
|
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|